IGM Biosciences Inc (NASDAQ: IGMS) is 25.51% higher on its value in year-to-date trading and has touched a low of $4.72 and a high of $22.50 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The IGMS stock was last observed hovering at around $9.46 in the last trading session, with the day’s gains setting it 0.97%.
Currently trading at $10.43, the stock is -12.13% and -26.87% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.2 million and changing 10.25% at the moment leaves the stock -4.78% off its SMA200. IGMS registered 79.83% gain for a year compared to 6-month gain of 19.75%. The firm has a 50-day simple moving average (SMA 50) of $14.3867 and a 200-day simple moving average (SMA200) of $10.97805.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -39.57% loss in the last 1 month and extending the period to 3 months gives it a 1.16%, and is 6.81% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 10.93% over the week and 11.56% over the month.
IGM Biosciences Inc (IGMS) has around 224 employees, a market worth around $620.21M and $2.92M in sales. Profit margin for the company is -7534.03%. Distance from 52-week low is 120.97% and -53.64% from its 52-week high. The company has generated returns on investments over the last 12 months (-186.14%).
The EPS is expected to grow by 31.95% this year
119.0 institutions hold shares in IGM Biosciences Inc (IGMS), with institutional investors hold 98.51% of the company’s shares. The shares outstanding are 33.18M, and float is at 17.52M with Short Float at 16.23%. Institutions hold 63.99% of the Float.
The top institutional shareholder in the company is BAKER BROS. ADVISORS LP with over 4.09 million shares valued at $28.1 million. The investor’s holdings represent 6.8042 of the IGMS Shares outstanding. As of 2024-06-30, the second largest holder is PRICE T ROWE ASSOCIATES INC /MD/ with 4.08 million shares valued at $28.0 million to account for 6.7789 of the shares outstanding. The other top investors are ARTAL GROUP S.A. which holds 3.33 million shares representing 5.5401 and valued at over $22.88 million, while REDMILE GROUP, LLC holds 5.1111 of the shares totaling 3.07 million with a market value of $21.11 million.
IGM Biosciences Inc (IGMS) Insider Activity
The most recent transaction is an insider sale by Weber Steven, the company’s PRINCIPAL ACCOUNTING OFFICER. SEC filings show that Weber Steven sold 469 shares of the company’s common stock on Sep 13 ’24 at a price of $11.54 per share for a total of $5412.0. Following the sale, the insider now owns 25543.0 shares.
IGM Biosciences Inc disclosed in a document filed with the SEC on Sep 13 ’24 that Takimoto Chris H (CHIEF MEDICAL OFFICER) sold a total of 1,487 shares of the company’s common stock. The trade occurred on Sep 13 ’24 and was made at $11.54 per share for $17158.0. Following the transaction, the insider now directly holds 0.15 million shares of the IGMS stock.
Still, SEC filings show that on Sep 13 ’24, Tahir Misbah (CHIEF FINANCIAL OFFICER) disposed off 1,487 shares at an average price of $11.54 for $17158.0. The insider now directly holds 122,694 shares of IGM Biosciences Inc (IGMS).
